WWARN News

Please visit WWARN's website for regular updates on malaria and sign up for the WWARN newsletter here. 

Credit: Pearl Gan
Thursday, 19 February 2015

Newsletter July 2014

Thursday, 19 February 2015

Newsletter Aug 2014

Thursday, 19 February 2015

Newsletter Sept 2014

Thursday, 19 February 2015

Newsletter Oct 2014

Thursday, 29 January 2015

UK government release report on malaria

Thursday, 29 January 2015

WHO September update on artemisinin resistance

Thursday, 29 January 2015

Malaria during pregnancy: providing evidence to support optimal antimalarial drug dosing

Thursday, 29 January 2015

Latest G-Finder report on global funding status for neglected diseases

Thursday, 29 January 2015

How malaria defeats our drugs

Thursday, 29 January 2015

Malaria eradication in an age of artemisinin resistance: an African perspective

Thursday, 29 January 2015

WHO World Health Day spotlight on vector-borne diseases

Thursday, 29 January 2015

The Great Malaria Debate at JITTM Bangkok

Thursday, 29 January 2015

Researchers identify a molecular marker for parasites resistant to malaria treatment

Thursday, 29 January 2015

New WWARN literature review explores the global extent of resistance in P. vivax

Our understanding of the extent and nature of resistance in P. vivax parasites is largely unknown. WWARN’s new literature review summarises the global extent of reduced P. vivax susceptibility to the frontline antimalarial chloroquine. You can also download our new generic P. vivax protocol - we wel...
Thursday, 29 January 2015

Have you read the WHO World Malaria Report?

Thursday, 29 January 2015

WWARN receives Brian Sharp Award at MIM Pan-African Malaria Conference 2013

Thursday, 29 January 2015

PLOS Medicine publishes paper recommending review of DP antimalarial dosing

Thursday, 29 January 2015

Acting Director announced at the WHO Global Malaria Programme

Thursday, 29 January 2015

African clinical trials awarded €683 million European Union (EU) investment

Thursday, 29 January 2015

WHO describe challenge with drug resistance and warn against using monotherapies